In the past week, APDN stock has gone down by -13.81%, with a monthly decline of -73.92% and a quarterly plunge of -79.89%. The volatility ratio for the week is 12.54%, and the volatility levels for the last 30 days are 18.46% for Applied Dna Sciences Inc The simple moving average for the past 20 days is -43.89% for APDN’s stock, with a -91.81% simple moving average for the past 200 days.
Is It Worth Investing in Applied Dna Sciences Inc (NASDAQ: APDN) Right Now?
The stock has a 36-month beta value of 0.84. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for APDN is 1.03M, and at present, short sellers hold a 5.83% of that float. On April 01, 2025, the average trading volume of APDN was 830.31K shares.
APDN) stock’s latest price update
The stock price of Applied Dna Sciences Inc (NASDAQ: APDN) has jumped by 9.04 compared to previous close of 1.66. Despite this, the company has seen a fall of -13.81% in its stock price over the last five trading days. accessnewswire.com reported 2025-04-01 that – Company Revamps Pharmacogenomics Go-To-Market Strategy, Targets Validated PGx Assay Towards Specific Use Cases – STONY BROOK, NY / ACCESS Newswire / April 1, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the “Company”), a leader in PCR-based DNA technologies, today announced that Applied DNA Clinical Labs (ADCL), its wholly-owned clinical laboratory subsidiary, is repositioning its TR8™ PGx pharmacogenomics testing service to offer tailored subpanels for indication-specific use cases in addition to full panel testing. The first subpanel under ADCL’s new go-to-market strategy is for the pre-emptive testing of patients with genetic variants of the DPYD gene that correlate to potentially reduced or absent DPD enzyme activity necessary to metabolize fluoropyrimidines, specifically capecitabine (branded Xeloda) and fluorouracil (5-FU), two chemotherapy drugs that are widely used as part of the standard of care treatment for patients with certain cancers.
Analysts’ Opinion of APDN
Many brokerage firms have already submitted their reports for APDN stocks, with ROTH Capital repeating the rating for APDN by listing it as a “Buy.” The predicted price for APDN in the upcoming period, according to ROTH Capital is $24 based on the research report published on February 12, 2021 of the previous year 2021.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see APDN reach a price target of $14, previously predicting the price at $18. The rating they have provided for APDN stocks is “Buy” according to the report published on January 14th, 2021.
H.C. Wainwright gave a rating of “Buy” to APDN, setting the target price at $12 in the report published on December 18th of the previous year.
APDN Trading at -71.29% from the 50-Day Moving Average
After a stumble in the market that brought APDN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.61% of loss for the given period.
Volatility was left at 18.46%, however, over the last 30 days, the volatility rate increased by 12.54%, as shares sank -71.41% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -80.88% lower at present.
During the last 5 trading sessions, APDN fell by -12.86%, which changed the moving average for the period of 200-days by -92.67% in comparison to the 20-day moving average, which settled at $3.2270. In addition, Applied Dna Sciences Inc saw -82.25% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for APDN
Current profitability levels for the company are sitting at:
- -3.53 for the present operating margin
- 0.34 for the gross margin
The net margin for Applied Dna Sciences Inc stands at -2.28. The total capital return value is set at -0.97. Equity return is now at value -100.40, with -65.89 for asset returns.
Based on Applied Dna Sciences Inc (APDN), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -21.87.
Currently, EBITDA for the company is -14.02 million with net debt to EBITDA at 0.68. When we switch over and look at the enterprise to sales, we see a ratio of -1.77. The receivables turnover for the company is 4.1for trailing twelve months and the total asset turnover is 0.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.72.
Conclusion
To sum up, Applied Dna Sciences Inc (APDN) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
